

# ΒΙΒΛΙΟΓΡΑΦΙΑ

1. Harris PC, Torres VE. Polycystic kidney disease. *Annu Rev Med.* 2009;60:321–37.
2. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. *J Cell Biol.* 2010 Nov 15;191(4):701–10.
3. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, et al. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol JASN.* 2016 Sep;27(9):2872–84.
4. Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2017 Nov 1;32(11):1857–65.
5. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggart-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. *Lancet Lond Engl.* 1999 Jan 9;353(9147):103–7.
6. Harris PC, Rossetti S. Molecular diagnostics for autosomal dominant polycystic kidney disease. *Nat Rev Nephrol.* 2010 Apr;6(4):197–206.
7. United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016.  
[https://www.usrds.org/2016/download/v2\\_ESRD\\_16.pdf](https://www.usrds.org/2016/download/v2_ESRD_16.pdf).
8. Sweeney WE, Avner ED. Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy. *Pediatr Res.* 2014 Jan;75(1–2):148–57.
9. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. *Kidney Int.* 2009 Jul;76(2):149–68.
10. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol JASN.* 2006 Nov;17(11):3013–9.
11. Halvorson CR, Bremmer MS, Jacobs SC. Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. *Int J Nephrol Renov Dis.* 2010;3:69–83.
12. Chebib FT, Torres VE. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. *Am J Kidney Dis Off J Natl Kidney Found.* 2016 Dec;67(5):792–810.
13. Patient Platform. <http://www.patient.co.uk/doctor/autosomal-dominant-polycystic-kidney-disease>.
14. Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2014 Feb;29(2):247–54.
15. Mikolajczyk AE, Te HS, Chapman AB. Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2017 Jan;15(1):17–24.
16. Chapman AB and Rahbari-OskuiFF. Renal Cystic Disorders. In: Wilcox CS et al. eds. *Therapy in Nephrology & Hypertension.* 3rd ed. Philadelphia, PA: Saunders; 2008.

## BIBΛΙΟΓΡΑΦΙΑ

17. Chauveau D, Pirson Y, Verellen-Dumoulin C, Macnicol A, Gonzalo A, Grünfeld JP. Intracranial aneurysms in autosomal dominant polycystic kidney disease. *Kidney Int.* 1994 Apr;45(4):1140–6.
18. Ecker T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. *J Am Soc Nephrol JASN.* 2001 Jan;12(1):194–200.
19. Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. *Kidney Int.* 2004 Oct;66(4):1561–9.
20. Nishiura JL, Neves RFCA, Eloi SRM, Cintra SMLF, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. *Clin J Am Soc Nephrol CJASN.* 2009 Apr;4(4):838–44.
21. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. *Kidney Int.* 1992 Dec;41(5):1311–9.
22. Idrizi A, Barbullushi M, Koroshi A, Dibra M, Bolleku E, Bajrami V, et al. Urinary tract infections in polycystic kidney disease. *Med Arh.* 2011;65(4):213–5.
23. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. *Clin J Am Soc Nephrol CJASN.* 2006 Jan;1(1):64–9.
24. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol JASN.* 1995 Jun;5(12):2048–56.
25. Rahman E, Niaz FA, Al-Suwaida A, Nahrir S, Bashir M, Rahman H, et al. Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: a single center study. *Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transplant Saudi Arab.* 2009 Sep;20(5):806–10.
26. Orskov B, Sørensen VR, Feldt-Rasmussen B, Strandgaard S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2012 Apr;27(4):1607–13.
27. Baker A, King D, Marsh J, Makin A, Carr A, Davis C, et al. Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians. *Clin Kidney J.* 2015 Oct;8(5):531–7.
28. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2016 Mar;31(3):337–48.
29. Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, et al. Predictors of autosomal dominant polycystic kidney disease progression. *J Am Soc Nephrol JASN.* 2014 Nov;25(11):2399–418.

## ΒΙΒΛΙΟΓΡΑΦΙΑ

30. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, et al. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol JASN*. 2018 Feb;29(2):571–8.
31. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol CJASN*. 2011 Mar;6(3):640–7.
32. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, et al. Volume progression in polycystic kidney disease. *N Engl J Med*. 2006 Dec 18;354(20):2122–30.
33. Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. *Kidney Int*. 2015 Jul;88(1):146–51.
34. Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol JASN*. 2016 Mar;27(3):942–51.